<DOC>
	<DOCNO>NCT00365859</DOCNO>
	<brief_summary>This study provide long-term safety data patient take aripiprazole 1 year . Most patient enrol study participate short-term study aripiprazole ( CN138-178 [ NCT00332241 ] CN138-179 [ NCT00337571 ] ) .</brief_summary>
	<brief_title>Study Aripiprazole Treatment Serious Behavioral Problems Children Adolescents With Autistic Disorder ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Behavioral Symptoms</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Inclusion Criteria Rollover : Completed 8 week treatment one follow doubleblind clinical trial : CN138178 [ NCT00332241 ] CN138179 [ NCT00337571 ] No significant protocol violation sufficient medical justification continue openlabel treatment aripiprazole Inclusion Criteria De Novo : Meets current Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIV TR ) diagnostic criterion AD demonstrate serious behavioral problem diagnosis confirm Autism Diagnostic InterviewRevised ( ADIR ) patient meet current Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIV TR ) diagnostic criterion AD history behavioral problem currently treat psychotropic medication Mental age least 18 month Male female 6 17 year age , inclusive , time enrollment Patients consider treatment resistant neuroleptic medication base lack therapeutic response 2 different neuroleptic treatment least 3 week Patients previously treat respond aripiprazole treatment The patient currently diagnose another disorder autism spectrum , include pervasive developmental disordernot otherwise specify ( PDDNOS ) , Asperger 's Disorder , Rett 's Disorder , FragileX Syndrome Childhood Disintegrative Disorder Current diagnosis bipolar disorder , psychosis , schizophrenia , major depression A seizure past year History severe head trauma stroke Nonpharmacologic therapy ( e.g . psychotherapy , behavior modification ) stable prior screening consistent throughout study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Serious behavioral problem child adolescent AD</keyword>
	<keyword>behavioral problem</keyword>
</DOC>